XNASMIST
Market cap99mUSD
Dec 24, Last price
1.86USD
1D
0.52%
1Q
23.16%
IPO
-89.67%
Name
Milestone Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
99.17
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.68%
Rev. gr., 5y
%
Revenues
1m
-80.00%
Net income
-60m
L+4.46%
CFO
-46m
L-11.52%
Earnings
Mar 19, 2025
Profile
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 1,000 -80.00% | 5,000 -66.67% | 15,000 | ||||
Cost of revenue | 62,098 | 65,122 | 58,073 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (61,098) | (60,122) | (43,073) | ||||
NOPBT Margin | |||||||
Operating Taxes | (1,254) | (220) | |||||
Tax Rate | |||||||
NOPAT | (61,098) | (58,868) | (42,853) | ||||
Net income | (59,685) 4.46% | (57,134) 34.01% | (42,633) -14.68% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 574 | 3,088 | 5,055 | ||||
BB yield | -0.80% | -1.84% | -1.84% | ||||
| Debt | |||||||
Debt current | 1,092 | 495 | 224 | ||||
Long-term debt | 53,232 | 4,487 | 1,172 | ||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | (11,679) | (59,603) | (112,745) | ||||
| Cash flow | |||||||
Cash from operating activities | (46,424) | (52,469) | (33,224) | ||||
CAPEX | (112) | (272) | |||||
Cash from investing activities | 4,756 | (57,124) | 70,000 | ||||
Cash from financing activities | 47,792 | 3,088 | 5,055 | ||||
FCF | (59,933) | (62,196) | (42,029) | ||||
| Balance | |||||||
Cash | 66,003 | 64,585 | 114,141 | ||||
Long term investments | |||||||
Excess cash | 65,953 | 64,335 | 113,391 | ||||
Stockholders' equity | (17,063) | 41,911 | 43,948 | ||||
Invested Capital | 86,155 | 26,928 | 69,350 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 42,956 | 42,450 | 41,834 | ||||
Price | 1.67 -57.83% | 3.96 -39.54% | 6.55 -2.24% | ||||
Market cap | 71,736 -57.33% | 168,103 -38.65% | 274,012 39.37% | ||||
EV | 60,057 | 108,500 | 161,267 | ||||
EBITDA | (61,006) | (60,033) | (42,980) | ||||
EV/EBITDA | |||||||
Interest | 2,554 | 1,254 | |||||
Interest/NOPBT | |||||||